Nov 29, 2024 · In this Review, we describe the current first-line treatment options for EGFR -mutant NSCLC, provide an overview of the mechanisms of acquired resistance to third-generation EGFR TKIs and...

1 day ago · Background Acquired MET alterations is one of the resistance mechanisms to advanced NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs). Several clinical trials combined MET-TKI (such as capmatinib, tepotinib, savolitinib) with EGFR-TKI to overcome MET alterations resistance. We performed this meta-analysis to determine the efficacy and safety of MET-TKI plus EGFR-TKI combined ...

After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring EGFR mutations.

Mar 27, 2025 · Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small-cell lung cancer (NSCLC) accounting for more than 85% of cases [].Approximately 20 years ago, the discovery of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and subsequent biomarker studies that identified the role of EGFR mutations in cancer etiology marked the beginning of the ...

In this article, we reviewed recently published studies to analyze the benefits of tyrosine kinase inhibitors, in particular, EGFR TKIs and ALK TKIs, as inducible treatments for NSCLC. Several clinical trials have recently presented their latest data, giving analysis of patient's survival benefits and adverse events.

Mar 13, 2025 · A proposed treatment scheme for EGFR-mutant NSCLC was developed based on this study’s results (right) to optimize the treatment recommendations in the NCCN Clinical Practice Guidelines in Oncology for Non–Small Cell Lung Cancer, Version 7.2024 (left). 21. Abbreviations: NSCLC, non–small cell lung cancer; TKI, tyrosine kinase inhibitor.

1 day ago · In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic non–small cell lung cancer (NSCLC).. Study Details

3 days ago · Mutations in the epidermal growth factor receptor (EGFR) are key drivers of non-small cell lung cancer (NSCLC) [].These mutations occur in approximately 40% of Asian patients with NSCLC [2, 3].Osimertinib is a third-generation irreversible oral EGFR-tyrosine kinase inhibitor (EGFR-TKI) that effectively and selectively inhibits activating EGFR mutations [exon 19 deletion (ex19 del) and L858R ...

Building on promising clinical results and growing insight into molecular biology and predictive biomarkers, EGFR TKIs achieved the previously unthinkable: they replaced first-line chemotherapy for some patients with advanced NSCLC.

Mar 13, 2025 · Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer and is typically linked to a poor prognosis [].At initial diagnosis, 46.8–61.2% of NSCLC patients identified as having stage IV disease [].Stage IV NSCLC is generally considered incurable, with palliative care serving as the cornerstone of management [].However, advancements in precision medicine for advanced NSCLC ...